Loading stock data…
LFMD
$4.54+0.26 (+6.07%)
LifeMD, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
LifeMD, Inc. in the Healthcare sector is trading at $4.54. Wall Street consensus targets $9.88 (8 analysts), implying a +117.5% move over the next 12 months. The stock is currently near its 52-week low of $2.56, remaining 5.6% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +117.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$4.54
Potential Downside
0%
Whystock Fair Value$4.54
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men's telehealth platf...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$221.64M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.77
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
61.99%
Volume
Today's trading volume
1.10M
Recent News
LifeMD, Inc. Q1 2026 Earnings Call Summary
Moby summary of LifeMD, Inc.'s Q1 2026 earnings call
LifeMD Q1 Earnings Call Highlights
LifeMD (NASDAQ:LFMD) reported first-quarter 2026 results that management said marked a strong start to the year, highlighted by revenue that topped guidance and record subscriber growth as the company continued shifting its weight management business toward branded GLP-1 therapies and expanded insur
LifeMD, Inc. (LFMD) Reports Q1 Loss, Tops Revenue Estimates
LifeMD (LFMD) delivered earnings and revenue surprises of -42.86% and +3.97%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
LifeMD (LFMD) Q1 2026 Earnings Transcript
Justin Schreiber: Thank you, and good afternoon, everyone. In weight management, sign-ups increased approximately 120% sequentially from Q4, and we exited the quarter with strong momentum across all of our key growth areas. As I outlined in our shareholder letter, I think about LifeMD, Inc. in very simple terms: quality care, quality products, quality revenue.
Medifast Q1 Earnings Call Highlights
Medifast (NYSE:MED) reported first-quarter 2026 results that management characterized as an early step toward stabilizing the business as it pivots from traditional weight loss to a broader metabolic health positioning amid continued disruption from GLP-1 drug adoption. On the company’s earnings ca